PTGIS

Across TCGA pan-cancer cohorts, PTGIS Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTGIS data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PTGIS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTGIS expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, ESCA, and STAD are the cancer types where PTGIS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.090	0.572	<.001	21	view →
ESCA	DFS	Median	All	0.023	0.533	<.001	18	view →
STAD	OS	Median	II,III,IV	0.184	0.710	.001	15	view →
SKCM	DFS	Median	II,III,IV	0.949	0.677	.018	7	view →
PRAD	DFS	Median	All	0.153	0.888	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTGIS–BLCA (DFS)

Open the BLCA breakdown →